Monrovia, CA -- (SBWIRE) -- 03/11/2010 -- Barbara Wirostko, Senior Medical Director, Team Lead Ophthalmology, Pfizer will present on Endothelin: A Potential Novel Mechanism for Future Drug Development in Ophthalmology at GTCbio’s 2nd Annual Ocular Disease Drug & Discovery Conference on May 27 – 28, 2010 in Boston, MA.

Barbara Wirostko will present her topic on Endothelin as a novel target. The benefits of the talk will cover the background and supporting data that exists to support this as a novel MOA and target, the rationale from a pathophysiologic perspective, the impact that modulating this target could have on ocular disease and pathology, and the clinical rationale for why such a novel approach is necessary.

GTCbio’s Ocular Disease conference will also bring together leading academics from Harvard, Columbia University, National Eye Institute as well as Industries from Pfizer, GlaxoSmithKline, and Genzyme. Updates on the age related macular degeneration, recent drug developments & mechanisms, ocular disease, and future of ocular disease therapeutics will be addressed and discussed.

GTCbio’s 2nd annual conference on Ocular Disease Drug and Discovery will provide cutting edge information and a chance to exchange ideas from leading experts in the field. Don’t miss this opportunity to register for GTCbio’s 2nd Annual Ocular Disease Drug and Discovery conference. Please check our web for the most up to date information: http://www.gtcbio.com/conferenceDetails.aspx?id=148